Lantheus Holdings Inc Revenue Growth Rates (LNTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lantheus Holdings Inc   (NASDAQ: LNTH)
 

LNTH's Revenue Growth by Quarter and Year

Lantheus Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LNTH/growth
https://api.csimarket.com/api/v1/companies/LNTH/fundamentals
https://api.csimarket.com/api/v1/companies/LNTH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
LNTH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 389.91
2nd Quarter June 388.18
1st Quarter March 376.92
FY 1,155.01

LNTHs Annual Revenue
Lantheus Holdings Inc 's Revenue in the fiscal year 2025 $ 1,540.95 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2024 $ 1,533.29 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2023 $ 1,295.54 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2022 $ 935.06 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2021 $ 425.21 millions




LNTH Revenue third quarter 2026 Y/Y Growth Comment
Lantheus Holdings Inc reported Revenue growth of 1.71% year on year in the third quarter 2026, to $ 389.91 millions, this is lower than Lantheus Holdings Inc 's recent average Revenue increase of 19.12%.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Lantheus Holdings Inc ' s Revenue increase of 1.71% ranks overall at the positon no. 2502 in the third quarter 2026.


LNTH Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.71 %
2nd Quarter June 2.69 %
1st Quarter March 1.13 %
FY   -

Financial Statements
Lantheus Holdings Inc 's third quarter 2026 Revenue $ 389.91 millions LNTH's Income Statement
Lantheus Holdings Inc 's third quarter 2025 Revenue $ 383.37 millions Quarterly LNTH's Income Statement


LNTH Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.45 %
2nd Quarter June 2.99 %
1st Quarter March -7.36 %
FY (Year on Year)   -


Back to LNTH Growth rate Comparisons >> Back to LNTH Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #359
Overall #2502

Revenue Y/Y Growth Statistics
High Average Low
134.43 % 19.12 % -22.98 %
(Dec 31 2022)   (Jun 30 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #359
Overall #2502
Revenue Y/Y Growth Statistics
High Average Low
134.43 % 19.12 % -22.98 %
(Dec 31 2022)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lantheus Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
61.22 % 4.07 % -27.22 %
(Mar 31 2022)  


LNTH's III. Quarter Q/Q Revenue Comment
Lantheus Holdings Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.45% quarter on quarter, to $ 389.91 millions.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Lantheus Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1354.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #189
Overall #1354
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #189
Overall #1354
Revenue Q/Q Growth Statistics
High Average Low
61.22 % 4.07 % -27.22 %
(Mar 31 2022)  


LNTH's III. Quarter Q/Q Revenue Comment
Lantheus Holdings Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.45% quarter on quarter, to $ 389.91 millions.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Lantheus Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1354.


Lantheus Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,561.89
Y / Y Revenue Growth (TTM) 2.38 %
Year on Year Revenue Growth Overall Ranking # 1981
Seqeuential Revenue Change (TTM) 0.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 2728


Cumulative Revenue growth Comment
Although Lantheus Holdings Inc 's Annual Revenue growth year on year were below company's average 19.48% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.38% year on year, from 2.3% in Jun 30 2026.

In the Healthcare sector 304 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1019 to 1981.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 305
Overall # 1981

Revenue TTM Y/Y Growth Statistics
High Average Low
119.91 %
 19.48 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2728
Cumulative Revenue growth Comment
Although Lantheus Holdings Inc 's Annual Revenue growth year on year were below company's average 19.48% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.38% year on year, from 2.3% in Jun 30 2026.

In the Healthcare sector 304 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1019 to 1981.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 305
Overall # 1981

Revenue TTM Y/Y Growth Statistics
High Average Low
119.91 %
19.48 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2728




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LNTH's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Integra Lifesciences Holdings Corp2.27%$ 2.268 millions
Align Technology inc 1.97%$ 1.966 millions
Pediatrix Medical Group Inc 1.72%$ 1.724 millions
Lantheus Holdings Inc 1.71%$ 1.708 millions
10x Genomics Inc 1.59%$ 1.591 millions
Bruker Corporation1.58%$ 1.581 millions
Boston Scientific Corporation1.44%$ 1.441 millions
Orthofix Medical Inc 1.14%$ 1.138 millions
Puma Biotechnology Inc 1.07%$ 1.067 millions
3m Company1.03%$ 1.028 millions


About Lantheus Holdings Inc Revenue Growth Rates (LNTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lantheus Holdings Inc (CIK 1521036).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-448622
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lantheus Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.